What are the future perspectives for anti-CD38 mAbs in the treatment of MM?
In this interview, Hermann Einsele discusses the future perspectives of anti-CD38 antibodies, highlighting their role in first-line treatment for both transplant-eligible and -ineligible patients as well as applications in the second line and smoldering MM. Einsele also discusses outcomes from key trials and outlines potential combinations of anti-CD38s with emerging therapies, including cereblon E3 ligase modulators (CELMoDs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies.
This educational resource is independently supported by Sanofi. All content was developed…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.